BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Northup PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, Superina RA, Roberts LN, Lisman T, Valla DC. Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021;73:366-413. [PMID: 33219529 DOI: 10.1002/hep.31646] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 28.0] [Reference Citation Analysis]
Number Citing Articles
1 de Franchis R, Bosch J, Garcia-tsao G, Reiberger T, Ripoll C, Abraldes JG, Albillos A, Baiges A, Bajaj J, Bañares R, Barrufet M, Benajiba L, Berzigotti A, Bureau C, Calvaruso V, Cardenas A, D’amico G, De Gottardi A, Dell’era A, Escorsell A, Fallowfield J, Ferral H, Francque S, Gaba R, Garcia-pagàn JC, Genescà J, Rodrigues SG, Gracia-sanscho J, Han G, Hernandez-gea V, Jia J, Kiladjian JJ, Krag A, Laleman W, La Mura V, Lens S, Luo X, Mandorfer M, Murad SD, Paradis V, Patch D, Piano S, Pinzani M, Plessier A, Primignani M, Procopet B, Rautou PE, Rudler M, Sarin SK, Schepis F, Senzolo M, Shah V, Shukla A, Tandon P, Tellez L, Thabut D, Thiele M, Trebicka J, Tripathi D, Tsochatzis E, Turco L, Turon F, Valla D, Villanueva C, Wanless I, Yoshiji H. BAVENO VII - RENEWING CONSENSUS IN PORTAL HYPERTENSION. Journal of Hepatology 2021. [DOI: 10.1016/j.jhep.2021.12.022] [Reference Citation Analysis]
2 Tosetti G, Primignani M. Author's reply: "Staging the pre-procedural prophylaxis in decompensated cirrhosis". Digestive and Liver Disease 2022. [DOI: 10.1016/j.dld.2022.05.003] [Reference Citation Analysis]
3 Lee DU, Han J, Fan GH, Hastie DJ, Kwon J, Lee KJ, Addonizio EA, Karagozian R. The clinical impact of chronic liver disease in patients undergoing transcatheter and surgical aortic valve replacement: Systematic analysis of the 2011-2017 US hospital database. Catheter Cardiovasc Interv 2021;98:E1044-57. [PMID: 34562288 DOI: 10.1002/ccd.29952] [Reference Citation Analysis]
4 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu., European Association for the Study of the Liver. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. J Hepatol 2022:S0168-8278(21)02033-X. [PMID: 35300861 DOI: 10.1016/j.jhep.2021.09.003] [Reference Citation Analysis]
5 Hidaka H, Uojima H. Ultrasonography in the diagnosis of complications in patients with portal hypertension. J Med Ultrason (2001) 2021. [PMID: 34787743 DOI: 10.1007/s10396-021-01158-3] [Reference Citation Analysis]
6 Radaelli F, Hassan C, Buscarini E, Dinis-Ribeiro M, Fuccio L. Second-generation thrombopoietin receptor agonists: New players in the management of cirrhotic patients undergoing therapeutic endoscopy? Dig Liver Dis 2021:S1590-8658(21)00250-4. [PMID: 34088596 DOI: 10.1016/j.dld.2021.05.007] [Reference Citation Analysis]
7 O'Shea RS, Davitkov P, Ko CW, Rajasekhar A, Su GL, Sultan S, Allen AM, Falck-Ytter Y. AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients With Cirrhosis. Gastroenterology 2021;161:1615-1627.e1. [PMID: 34579936 DOI: 10.1053/j.gastro.2021.08.015] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Primignani M, Tosetti G, Tripodi A. Implementing pre-procedural thrombopoietin receptor agonists in cirrhotic patients with severe thrombocytopenia: Indiscriminate, selective or unneeded? Dig Liver Dis 2021;53:1394-5. [PMID: 34446353 DOI: 10.1016/j.dld.2021.08.004] [Reference Citation Analysis]
9 Gilbert-kawai N, Hogan B, Milan Z. Perioperative management of patients with liver disease. BJA Education 2022. [DOI: 10.1016/j.bjae.2021.11.006] [Reference Citation Analysis]
10 Varlas VN, Bohîlțea R, Gheorghe G, Bostan G, Angelescu GA, Penes ON, Bors RG, Cloțea E, Bacalbasa N, Diaconu CC. State of the Art in Hepatic Dysfunction in Pregnancy. Healthcare (Basel) 2021;9:1481. [PMID: 34828527 DOI: 10.3390/healthcare9111481] [Reference Citation Analysis]
11 De Maria C, Galante A, Fasoli A, De Gottardi A. When and how to use direct oral anticoagulants in patients with advanced chronic liver disease? Curr Opin Pharmacol 2021;60:111-6. [PMID: 34403992 DOI: 10.1016/j.coph.2021.07.006] [Reference Citation Analysis]
12 Rose PD, Au M, Woodman RJ, Tee D, Chinnaratha MA. Pre-procedural use of thrombopoietin-receptor agonists in cirrhosis and severe thrombocytopenia: A systematic review and meta-analysis. Dig Liver Dis 2021:S1590-8658(21)00384-4. [PMID: 34373229 DOI: 10.1016/j.dld.2021.07.015] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Perez I, Bolte FJ, Bigelow W, Dickson Z, Shah NL. Step by Step: Managing the Complications of Cirrhosis. Hepat Med 2021;13:45-57. [PMID: 34079394 DOI: 10.2147/HMER.S278032] [Reference Citation Analysis]
14 Intagliata NM, Davitkov P, Allen AM, Falck-Ytter YT, Stine JG. AGA Technical Review on Coagulation in Cirrhosis. Gastroenterology 2021;161:1630-56. [PMID: 34579937 DOI: 10.1053/j.gastro.2021.09.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Roberts LN. Rebalanced hemostasis in liver disease: a misunderstood coagulopathy. Hematology Am Soc Hematol Educ Program 2021;2021:485-91. [PMID: 34889414 DOI: 10.1182/hematology.2021000283] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Knight GM, Clark J, Boike JR, Maddur H, Ganger DR, Talwar A, Riaz A, Desai K, Mouli S, Hohlastos E, Garcia Pagan JC, Gabr A, Stein B, Lewandowski R, Thornburg B, Salem R. TIPS for Adults Without Cirrhosis With Chronic Mesenteric Venous Thrombosis and EHPVO Refractory to Standard-of-Care Therapy. Hepatology 2021. [PMID: 34021505 DOI: 10.1002/hep.31915] [Reference Citation Analysis]
17 Biolato M, Paratore M, Di Gialleonardo L, Marrone G, Grieco A. Direct oral anticoagulant administration in cirrhotic patients with portal vein thrombosis: What is the evidence? World J Hepatol 2022; 14(4): 682-695 [DOI: 10.4254/wjh.v14.i4.682] [Reference Citation Analysis]
18 Schutgens REG, Lisman T. Tranexamic Acid Is Not a Universal Hemostatic Agent. Hemasphere 2021;5:e625. [PMID: 34291198 DOI: 10.1097/HS9.0000000000000625] [Reference Citation Analysis]
19 Zanetto A, Campello E, Bulato C, Gavasso S, Farinati F, Russo FP, Tormene D, Burra P, Senzolo M, Simioni P. Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.03.009] [Reference Citation Analysis]
20 Ronca V, Barabino M, Santambrogio R, Opocher E, Hodson J, Bertolini E, Birocchi S, Piccolo G, Battezzati P, Cattaneo M, Podda GM. Impact of Platelet Count on Perioperative Bleeding in Patients With Cirrhosis Undergoing Surgical Treatments of Liver Cancer. Hepatol Commun 2021. [PMID: 34716696 DOI: 10.1002/hep4.1806] [Reference Citation Analysis]
21 Benmassaoud A, Rodger M. Challenging anticoagulation cases: Acute extensive portal vein thrombosis in a patient without cirrhosis - Evidence-based management of a rare clinical entity. Thromb Res 2021;206:133-6. [PMID: 34464871 DOI: 10.1016/j.thromres.2021.08.013] [Reference Citation Analysis]
22 Zanetto A, Campello E, Bulato C, Gavasso S, Saggiorato G, Shalaby S, Burra P, Angeli P, Senzolo M, Simioni P. Global hemostatic profiling in patients with decompensated cirrhosis and bacterial infections. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100493] [Reference Citation Analysis]
23 Shenoy A, Louissaint J, Shannon C, Tapper EB, Lok AS. Viscoelastic Testing Prior to Non-surgical Procedures Reduces Blood Product Use Without Increasing Bleeding Risk in Cirrhosis. Dig Dis Sci 2022. [PMID: 35122595 DOI: 10.1007/s10620-021-07376-6] [Reference Citation Analysis]
24 Shukla A, Giri S. Portal Vein Thrombosis in Cirrhosis. Journal of Clinical and Experimental Hepatology 2021. [DOI: 10.1016/j.jceh.2021.11.003] [Reference Citation Analysis]
25 Valla DC. Recommendations for management of portal vein thrombosis in cirrhosis. J Dig Dis 2021;22:174-5. [PMID: 33733596 DOI: 10.1111/1751-2980.12982] [Reference Citation Analysis]
26 Li Z, Xu WT, Xu XB, Qi XS. Heparins for prevention and treatment of venous thromboembolism in cirrhosis: Research advances. Shijie Huaren Xiaohua Zazhi 2022; 30(9): 381-386 [DOI: 10.11569/wcjd.v30.i9.381] [Reference Citation Analysis]
27 Galante A, De Gottardi A. Portal vein thrombosis: an overview of current treatment options. Acta Gastroenterol Belg 2021;84:327-32. [PMID: 34217184 DOI: 10.51821/84.2.327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Tian Y, Qi X, Aljbri A, Xu K, Zhong H. Case Report: Pancreatic Neuroendocrine Tumor With Liver Metastasis and Portal Vein Thrombosis. Front Oncol 2022;11:809129. [DOI: 10.3389/fonc.2021.809129] [Reference Citation Analysis]
29 Campello E, Zanetto A, Bulato C, Maggiolo S, Spiezia L, Russo FP, Gavasso S, Mazzeo P, Tormene D, Burra P, Angeli P, Senzolo M, Simioni P. Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. Liver Int 2021. [PMID: 34219335 DOI: 10.1111/liv.15001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Lisman T, Procopet B. Fresh frozen plasma in treating acute variceal bleeding: Not effective and likely harmful. Liver Int 2021;41:1710-2. [PMID: 34273225 DOI: 10.1111/liv.14988] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Evans CR, Cuker A, Crowther M, Pishko AM. Prophylactic fresh frozen plasma versus prothrombin complex concentrate for preprocedural management of the coagulopathy of liver disease: A systematic review. Res Pract Thromb Haemost 2022;6. [DOI: 10.1002/rth2.12724] [Reference Citation Analysis]
32 Zanetto A, Campello E, Bulato C, Gavasso S, Saggiorato G, Shalaby S, Spiezia L, Cillo U, Farinati F, Russo FP, Burra P, Senzolo M, Simioni P. More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients With Cirrhosis With Versus Without HCC. Hepatol Commun 2021;5:1987-2000. [PMID: 34558850 DOI: 10.1002/hep4.1781] [Reference Citation Analysis]
33 Koh JH, Liew ZH, Ng GK, Liu HT, Tam YC, De Gottardi A, Wong YJ. Efficacy and safety of direct oral anticoagulants versus vitamin K antagonist for portal vein thrombosis in cirrhosis: A systematic review and meta-analysis. Dig Liver Dis 2021:S1590-8658(21)00408-4. [PMID: 34393072 DOI: 10.1016/j.dld.2021.07.039] [Reference Citation Analysis]
34 Tosetti G, Farina E, Caccia R, Sorge A, Berzuini A, Valenti L, Prati D, Tripodi A, Lampertico P, Primignani M. Preprocedural prophylaxis with blood products in patients with cirrhosis: Results from a survey of the Italian association for the study of the liver (AISF). Digestive and Liver Disease 2022. [DOI: 10.1016/j.dld.2022.03.017] [Reference Citation Analysis]
35 Wang L, Guo X, Shao X, Xu X, Zheng K, Wang R, Chawla S, Basaranoglu M, Qi X. Association of endoscopic variceal treatment with portal venous system thrombosis in liver cirrhosis: a case–control study. Therap Adv Gastroenterol 2022;15:175628482210875. [DOI: 10.1177/17562848221087536] [Reference Citation Analysis]
36 Primignani M, Tosetti G, Tripodi A. Thrombopoietin receptor agonists before elective invasive procedures in cirrhotic patients with thrombocytopenia: ready to start? Dig Liver Dis 2021;53:1364-5. [PMID: 34210622 DOI: 10.1016/j.dld.2021.06.008] [Reference Citation Analysis]
37 Tu H, Li M, Chen Z, Zhao J, Wang H, Qian J, Wei C, Yang Y, Zhu Y, Zuo L. Plateletcrit for predicting prognosis in patients with hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloid. J Clin Lab Anal 2022;:e24240. [PMID: 35034375 DOI: 10.1002/jcla.24240] [Reference Citation Analysis]
38 Lucas F, Stecker MS, Pozdnyakova O, Connors JM, Battinelli EM. Rivaroxaban-calibrated chromogenic anti-Xa assay in cirrhosis: Use to rule out disseminated intravascular coagulation. Res Pract Thromb Haemost 2021;5:e12594. [PMID: 34646974 DOI: 10.1002/rth2.12594] [Reference Citation Analysis]
39 Mansour N, Öcal O, Gerwing M, Köhler M, Deniz S, Heinzow H, Steib C, Angele MK, Seidensticker M, Ricke J, Wildgruber M. Interventional recanalization therapy in patients with non-cirrhotic, non-malignant portal vein thrombosis: comparison between transjugular versus transhepatic access. Abdom Radiol. [DOI: 10.1007/s00261-022-03411-w] [Reference Citation Analysis]
40 Premkumar M, Bhujade H, Karki T, Chaluvashetty SB, Kaur H, Duseja AK, Singh V. New Portal Vein Thrombosis in Cirrhosis-is the thrombophilia exacerbated due to Vaccine or COVID-19? J Clin Exp Hepatol 2021. [PMID: 34776709 DOI: 10.1016/j.jceh.2021.10.149] [Reference Citation Analysis]
41 Northup PG, Lisman T, Roberts LN. Treatment of bleeding in patients with liver disease. J Thromb Haemost 2021;19:1644-52. [PMID: 33974330 DOI: 10.1111/jth.15364] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Primignani M, Tosetti G. Direct oral anticoagulants for portal vein thrombosis in cirrhosis: Good news from meta-analysis? Dig Liver Dis 2022;54:54-5. [PMID: 34688574 DOI: 10.1016/j.dld.2021.09.018] [Reference Citation Analysis]
43 Blasi A, Patel VC, Spanke ENHE, Adelmeijer J, Stamouli M, Zamalloa A, Corcoran E, Calvo A, Fernandez J, Bernal W, Lisman T. Fibrin clot quality in acutely ill cirrhosis patients: Relation with outcome and improvement with coagulation factor concentrates. Liver Int 2021. [PMID: 34894081 DOI: 10.1111/liv.15132] [Reference Citation Analysis]
44 Driever EG, Bernal W, Lisman T. Reply. Hepatology 2021. [PMID: 34951045 DOI: 10.1002/hep.32214] [Reference Citation Analysis]
45 Liou P, Kato T, Fishbein T. Surgical Perspectives on the American Association for the Study of Liver Diseases Guideline for Anticoagulation and Implications for Liver Transplantation. Liver Transpl 2021;27:580-3. [PMID: 33486844 DOI: 10.1002/lt.25990] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Driever EG, Lisman T. Effects of Inflammation on Hemostasis in Acutely Ill Patients with Liver Disease. Semin Thromb Hemost 2022. [PMID: 35135033 DOI: 10.1055/s-0042-1742438] [Reference Citation Analysis]
47 Luther J, Friedman LS. Management of Thrombocytopenia and Coagulopathy in Patients with Chronic Liver Disease Undergoing Therapeutic Endoscopic Interventions. Clin Liver Dis 2022;26:1-12. [PMID: 34802655 DOI: 10.1016/j.cld.2021.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Ageno W. Treatment of Atypical Clots. Hamostaseologie 2022;42:10-8. [PMID: 35196729 DOI: 10.1055/a-1669-3336] [Reference Citation Analysis]
49 Kishore S, Khaja MS, Thornburg B, Sharma AM, Knuttinen MG, Shamoun F, Mantha S, Desai KR, Sista AK, Black SA, O'Sullivan GJ, Kaufman JA, Hofmann LV, Winokur RS. Antithrombotic Therapy After Venous Interventions: AJR Expert Panel Narrative Review. AJR Am J Roentgenol 2022. [PMID: 35352572 DOI: 10.2214/AJR.22.27413] [Reference Citation Analysis]
50 Xu S, Guo X, Yang B, Romeiro FG, Primignani M, Méndez-Sánchez N, Yoshida EM, Mancuso A, Tacke F, Noronha Ferreira C, De Stefano V, Qi X. Evolution of Nonmalignant Portal Vein Thrombosis in Liver Cirrhosis: A Pictorial Review. Clin Transl Gastroenterol 2021;12:e00409. [PMID: 34597281 DOI: 10.14309/ctg.0000000000000409] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Ju C, Li X, Gadani S, Kapoor B, Partovi S. Portal Vein Thrombosis: Diagnosis and Endovascular Management. Rofo 2021. [PMID: 34649289 DOI: 10.1055/a-1642-0990] [Reference Citation Analysis]
52 Yeoh SW, Kok HK. Transjugular intrahepatic portosystemic shunts in portal vein thrombosis: A review. J Dig Dis 2021. [PMID: 34323378 DOI: 10.1111/1751-2980.13035] [Reference Citation Analysis]
53 Kobe A, Puippe G, Müllhaupt B, Pfammatter T. Recanalization of Chronic Noncirrhotic, Nonmalignant Splanchnic Thromboses is Feasible: A Transsplenic Assisted Patient-Tailored Approach. J Vasc Interv Radiol 2021;32:1377-85. [PMID: 34462082 DOI: 10.1016/j.jvir.2021.05.012] [Reference Citation Analysis]
54 Lisman T, Caldwell SH, Intagliata NM. Haemostatic alterations and management of haemostasis in patients with cirrhosis. J Hepatol 2022;76:1291-305. [PMID: 35589251 DOI: 10.1016/j.jhep.2021.11.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Yeo JW, Law MSN, Lim JCL, Ng CH, Tan DJH, Tay PWL, Syn N, Tham HY, Huang DQ, Siddiqui MS, Iyer S, Muthiah M. Meta-analysis and systematic review: Prevalence, graft failure, mortality, and post-operative thrombosis in liver transplant recipients with pre-operative portal vein thrombosis. Clin Transplant 2021;:e14520. [PMID: 34687558 DOI: 10.1111/ctr.14520] [Reference Citation Analysis]
56 Li B, He Q, Lu G, Hong C, Chen J. Minor role of hemostatic alternation in portal vein thrombosis pathogenesis revealed by global measurement. J Hepatol 2021:S0168-8278(21)02031-6. [PMID: 34509525 DOI: 10.1016/j.jhep.2021.09.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Lisman T, Hernandez-Gea V, Magnusson M, Roberts L, Stanworth S, Thachil J, Tripodi A. The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease. J Thromb Haemost 2021;19:1116-22. [PMID: 33792172 DOI: 10.1111/jth.15239] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
58 Martens K, McMurry HS, Koprowski S, Hum J, Haraga J, Jou JH, Shatzel JJ. Anticoagulation in Cirrhosis: Evidence for the Treatment of Portal Vein Thrombosis and Applications for Prophylactic Therapy. J Clin Gastroenterol 2022. [PMID: 35537133 DOI: 10.1097/MCG.0000000000001713] [Reference Citation Analysis]
59 Limdi JK. Editorial commentary on Indian Journal of Gastroenterology-September-October 2021. Indian J Gastroenterol 2021. [PMID: 34665426 DOI: 10.1007/s12664-021-01219-y] [Reference Citation Analysis]
60 Gonçalves A. Primary Budd-Chiari Syndrome With Right Atrial Extension: A Rare Presentation of Intrahepatic Cholangiocarcinoma. Cureus 2021;13:e18935. [PMID: 34812319 DOI: 10.7759/cureus.18935] [Reference Citation Analysis]
61 Bos I, Blondeau M, Wouters D, Camus C, Houssel-Debry P, van der Plas WS, Nieuwenhuis LM, Bardou-Jacquet E, Lisman T, de Meijer VE, Porte RJ, Rayar M. Therapeutic anticoagulation after liver transplantation is not useful among patients with pre-transplant Yerdel-grade I/II portal vein thrombosis: A two-center retrospective study. J Thromb Haemost 2021. [PMID: 34297481 DOI: 10.1111/jth.15472] [Reference Citation Analysis]
62 Blasi A, Machlab S, Risco R, Costa-Freixas JP, Hernández-Cely G, Horta D, Bofill A, Ruiz-Ramirez P, Profitos J, Sanahuja JM, Fernandez-Simon A, Gómez MV, Sánchez-Delgado J, Cardenas A. A multicenter analysis of the role of prophylactic transfusion of blood products in patients with cirrhosis and esophageal varices undergoing endoscopic band ligation. JHEP Rep 2021;3:100363. [PMID: 34765959 DOI: 10.1016/j.jhepr.2021.100363] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
63 Molvar C, Amin P. Portal Vein Thrombosis In Cirrhosis: Interventional Treatment Options. Curr Gastroenterol Rep 2021;23:24. [PMID: 34654971 DOI: 10.1007/s11894-021-00826-1] [Reference Citation Analysis]
64 Senzolo M, Piano S, Shalaby S, Tonon M, Tonello S, Zanetto A, Sacerdoti D, Simioni P, Bombonato G, Burra P, Angeli P. Comparison of Fondaparinux and Low-Molecular-Weight Heparin in the Treatment of Portal Vein Thrombosis in Cirrhosis. Am J Med 2021:S0002-9343(21)00389-2. [PMID: 34197784 DOI: 10.1016/j.amjmed.2021.05.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Zenlander R, Havervall S, Magnusson M, Engstrand J, Ågren A, Thålin C, Stål P. Neutrophil extracellular traps in patients with liver cirrhosis and hepatocellular carcinoma. Sci Rep 2021;11:18025. [PMID: 34504150 DOI: 10.1038/s41598-021-97233-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Scheiner B, Balcar L, Johanna Nussbaumer R, Weinzierl J, Paternostro R, Simbrunner B, Hartl L, Jachs M, Bauer D, Stättermayer AF, Semmler G, Pinter M, Ay C, Quehenberger P, Trauner M, Reiberger T, Lisman T, Mandorfer M. Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2021.12.038] [Reference Citation Analysis]
67 Sack JS, Zucker SD. Safety of TEE in Patients with Cirrhosis and Esophageal Varices. J Am Soc Echocardiogr 2022:S0894-7317(22)00002-5. [PMID: 34998964 DOI: 10.1016/j.echo.2022.01.002] [Reference Citation Analysis]